ASNA1 Monoclonal antibody, PBS Only (Capture)

ASNA1 Monoclonal Antibody for WB, IHC, IF/ICC, Cytometric bead array, Indirect ELISA

Host / Isotype

Mouse / IgG1

Reactivity

human, mouse, rat, pig, chicken

Applications

WB, IHC, IF/ICC, Cytometric bead array, Indirect ELISA

Conjugate

Unconjugated

CloneNo.

1B7C11

Cat no : 66346-1-PBS

Synonyms

TRC40, ATPase GET3, ASNA 1, Arsenite-stimulated ATPase, Arsenical pump-driving ATPase


☆対象製品が30%オフ!組換えタンパク質&免染用試薬 >>> キャンペーン実施中!


Tested Applications

Recommended dilution

ApplicationDilution
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Product Information

66346-1-PBS targets ASNA1 as part of a matched antibody pair:

MP50801-1: 66346-1-PBS capture and 66346-2-PBS detection (validated in Cytometric bead array)

Unconjugated mouse monoclonal antibody pair in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation.

This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.

Tested Reactivity human, mouse, rat, pig, chicken
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen ASNA1 fusion protein Ag7936 相同性解析による交差性が予測される生物種
Full Name arsA arsenite transporter, ATP-binding, homolog 1 (bacterial)
Calculated molecular weight 38.7 kDa
Observed molecular weight 37-41 kDa
GenBank accession numberBC002651
Gene symbol ASNA1
Gene ID (NCBI) 439
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.

Background Information

ASNA1 (also known as TRC40) is a highly conserved ATPase involved in efflux of arsenite and antimonite. Reduced ASNA1 expression is associated with significant inhibition of cell growth, increased apoptosis and increased sensitivity to arsenite.Thus ASNA1 is proposed to be a target to overcome resistance to cancer chemotherapy. In addition, ASNA1 has been identified as an ER targeting factor for tail-anchored proteins in the posttranslational membrane insertion pathway.